Phio Pharmaceuticals
| Region | Nordamerika |
| ISIN | US71880W2044 |
| Sektor | Biotechnologie |
| Website | http://www.phiopharma.com |
Phio Pharmaceuticals is focused on developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYLTM) therapeutic platform. Immunotherapies harness our immune system to restore surveillance of tumors that evade detection – a potential curative medicine. INTASYLTM therapeutics can be used as a standalone treatment or in combination with other modalities.
| Titel | Autor | Datum |
|---|---|---|
|
In Wahrheit 100 Mal so viel wert?
|
sharedeals | vor über 5 Jahren |
| Titel | Datum |
|---|---|
| MISC, Gentari partner up on ammonia shipping and floating solutions | vor ungefähr 5 Monaten |
| Bumi Armada's 3Q net profit rises 19%, no update on merger with MISC's offshore unit | vor ungefähr 5 Monaten |
| Bumi Armada and MISC plan merger to boost offshore market position | vor ungefähr 6 Monaten |
| MISC likely to hold 68% stake in Bumi Armada merger, with RM14.6b combined valuation | vor ungefähr 6 Monaten |
| Bumi Armada, MISC, Berjaya Food, Mr DIY, Prolintas, Lysaght, Keyfield, Teo Seng, YTL Power, Ranhill Utilities, Seal and LBS Bina | vor ungefähr 6 Monaten |
| Diese Aktien könnten Dich auch interessieren | |
|---|---|
| PayPal (1 Artikel) | |
| Palatin Technologies (4 Artikel) | |
| Premier Gold Mines (1 Artikel) | |
| QIAGEN (1 Artikel) | |
| Alle anzeigen | |